Paulo Neves

R&D

Paulo Neves, CMO of Xeltis, discusses transformative implants that enable the natural creation of living and long-lasting vessels.

News

Eli Lilly's first major readout at ESMO comes from a phase 1 trial of its FRα-targeting sofe-m in platinum-sensitive ovarian cancer (PSOC).

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.